Zynex, Inc. reported its financial results for the three and nine months ended September 30, 2024. The company’s revenue increased by 15% to $23.1 million for the nine months ended September 30, 2024, compared to $20.1 million for the same period in 2023. Net income for the nine months ended September 30, 2024 was $2.3 million, compared to a net loss of $1.4 million for the same period in 2023. The company’s cash and cash equivalents increased to $14.4 million as of September 30, 2024, compared to $10.3 million as of December 31, 2023. The company’s total assets increased to $43.4 million as of September 30, 2024, compared to $36.4 million as of December 31, 2023.
Summary and Analysis of Key Points
Overview of Financial Performance Zynex, Inc. is a medical device company that operates primarily in the electrotherapy and pain management products segment. The company’s key financial highlights for the three and nine months ended September 30, 2024 include:
Revenue and Profit Trends Zynex’s revenue is primarily composed of device sales/rentals and supplies sales. Device revenue decreased 12% in the three-month period but increased 5% in the nine-month period, due to factors like decreased sales force headcount and an increase in lower-priced distributed products, offset by the growth in device orders. Supplies revenue increased 6% and 7% in the three and nine-month periods, respectively, driven by the larger customer base from increased device orders.
The company’s profitability declined in the three and nine-month periods compared to the same periods in 2023. Net income decreased 33% and 58% in the three and nine-month periods, respectively. This was primarily due to increases in general and administrative expenses, which grew 20% and 21% in the respective periods, related to higher professional fees, R&D costs, and compensation expenses.
Strengths and Weaknesses Zynex’s key strengths include:
Weaknesses include:
Outlook Zynex appears to be navigating the post-COVID environment well, with limited disruptions to its operations. However, the company faces headwinds in the form of rising costs and declining profitability. To maintain its growth trajectory, Zynex will need to carefully manage its expenses, particularly in the general and administrative areas, while continuing to drive device order and revenue growth. The company’s strong cash position provides a buffer, but sustained profitability will be crucial for long-term success.